Abstract: The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 weeks. The method is useful in the treatment of stroke and severe head trauma patients and maximizes the chances for a full or substantially full recovery of the patient.

Abstract: A therapeutic method is provided to alleviate the tobacco withdrawal syndrome, the symptoms of nicotine withdrawal or the management of human body weight in nicotine-experienced or nicotine-naive individuals, comprising of administering an amount of nicotine metabolites or a pharmaceutically acceptable salts thereof to a human in need of such treatment, in an amount which is effective to reduce or eliminate at least one of the symptoms of the tobacco withdrawal syndrome, nicotine withdrawal or manage human body weight.

Abstract: A therapeutic method is provided to alleviate the tobacco withdrawal syndrome, the symptoms of nicotine withdrawal or the management of human body weight in nicotine-experienced or nicotine-naive individuals, comprising of administering an amount of nicotine metabolites or a pharmaceutically acceptable salts thereof to a human in need of such treatment, in an amount which is effective to reduce or eliminate at least one of the symptoms of the tobacco withdrawal syndrome, nicotine withdrawal or manage human body weight.

Abstract: This invention is directed to a pharmacologically acceptable composition for inhibiting or treating hemorrhagic shock in a mammal. The composition includes a K.sub.ATP inhibitor and a pharmacologically acceptable carrier, with the K.sub.ATP inhibitor being present in an amount sufficient to inhibit or treat hemorrhagic shock in the mammal. The invention is also directed to a method for inhibiting or treating hemorrhagic shock in a mammal. The method includes administering to the mammal an amount of a K.sub.ATP channel inhibitor sufficient to inhibit or treat hemorrhagic shock in the mammal. In a preferred form of the invention, the K.sub.

Abstract: A method for treating infections, bacterial, fungal and parasitic in origin, especially infections of organs such as the vagina and skin, is provided and involves administering to a patient in need thereof a composition comprising boric acid and acetic acid, in effective amounts. Such a composition is especially useful as a broad based treatment of vaginal infections of unknown bacterial or fungal origin and can be used without the need for medical diagnosis or while such a diagnosis is being determined. Such a composition is effective, safe, providing an alternative to existing forms of treatment which are toxic and is environmentally friendly.

Abstract: Methods are provided for treating sepsis/endotoxin-induced acute renal failure, and renal vasoconstriction and catecholamine-induced renal and mesenteric vasconstriction by administering to a patient a therapeutically effective amount of a composition comprising at least one drug with Type IV phosphodiesterase inhibiting activity or any combination thereof and a pharmaceutically acceptable carrier.

Abstract: Anti-pruritic compositions and methods of using the compositions for the prevention or treatment of pruritus comprising: ##STR1## wherein M is ##STR2## wherein: R, R.sup.2, R.sup.3, R.sup.4, R.sup.7, Ar.sup.1 and Ar.sup.2 are as defined in the specification in a pharmaceutically acceptable carrier.

Abstract: Nerve growth factor production accelerating agents containing oxazopyrroloquinolines, pyrroquinolinequinones and/or their esters as active ingredient are provided. As the oxazopyrroloquinolines and their esters exhibit such production accelerating activity, they are suitably utilized for preventing and treating functional disorders of central nervous system, particularly, Alzheimer's dementia, cerebral ischemia and spinal trauma, as well as for functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma and diabetic neurosis. As the pyrroquinolinequinones and their esters exhibit strong nerve growth factor production accelerating activity, they are suitably utilized for preventing and treating functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma, diabetic neurosis, etc.

Abstract: The invention relates to the use of zucapsaicin (cis-8-methly-N-vanillly-6-nonenamide), the cis-isomer of capsaicin, to treat myocardial disorders, including the prevention, suppression or reversal of an abnormal cardiac rhythm, such as ventricular tachycardia. In vitro, zucapsaicin exhibits electrophysiologic properties distinct from capsaicin. In contrast to capsaicin, zucapsaicin significantly shortens the action potential duration at a dose of 10.sup.-5 M and has no effect on the amplitude of Phase 1 of the action potential in normal Purkinje cells. Zucapsaicin also prevents the induction of ventricular tachycardia of focal Purkinje origin when given intravenously after coronary occlusion in a dog model of acute myocardial infarction.

Abstract: A method to prevent or inhibit the development of arterial plaque, comprising the steps of:a. administering to a subject an amount of a green porphyrin compound effective to prevent or inhibit said development; andb. allowing the inhibition to occur in the absence of irradiation with light absorbed by the green porphyrin,or a pharmaceutical composition for preventing or inhibiting the development of arterial plaque. The composition comprises:a. an amount of a green porphyrin compound effective to prevent or inhibit the development when administered to a subject in need of such treatment, even in the absence of irradiation with light absorbed by said the green porphyrin; andb. a pharmaceutically acceptable excipient.The administration of the green porphyrin need not be accompanied by any purposeful irradiation with light.

Abstract: The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 weeks. The method is useful in the treatment of stroke and severe head trauma patients and maximizes the chances for a full or substantially full recovery of the patient. Combination treatment regimens are also disclosed along with compositions for use therewith.

Abstract: In accordance with the present invention, a method and device is provided for administering therapeutically effective doses of the drug azospirone transdermally for treating psychogenic symptomatologies. One embodiment of the present invention comprises an effective amount of solubilized azospirone in a transdermal drug delivery device. By practicing the present invention, constant blood concentrations of azospirone can be maintained over a prolonged period of time, side effects can be minimized with maximal patient compliance.

Abstract: A solid oral dosage form for the treatment of gastrointestinal disorders comprising a therapeutically effective amount of a therapeutically effective amount of guanidinothiazole compound; and a therapeutically effective amount of an antacid wherein the pharmaceutical and an antacid are separated by a barrier which is substantially impermeable to an antacid.

Abstract: 8-Hydroxyquinoline is useful in the topical treatment of inflammatory proliferative skin diseases, especially psoriasis. It should be applied from an essentially anhydrous vehicle.

Abstract: A therapeutical method for treating endotoxic shock which comprises administering to a patient in need thereof a (3-phthalidyliden) alkyl ester of carnitine or alkanoyl carnitine, is disclosed.

Abstract: A syrup containing N-acetyl-cysteine, stable for at least two years, having pleasant taste and smell, consists of an aqueous solution of NAC, a sweetening agent and a thickening agent. The solution can also contain a flavoring agent and a preservative. The pH is between 5 and 8.

Abstract: Methods and pharmaceutical compositions for reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia.

Abstract: A pharmaceutical composition having an antialcoholic and nootropic effect which is administered sublingually. The active ingredients of the composition are the amino acid L-threonine or a pharmaceutically acceptable salt thereof and vitamin B.sub.6. A method for reducing and eliminating the pathological attraction to alcohol and treatment of alcohol abstinence syndrome, as well as a method for increasing attention comprises sublingual administration of an effective amount of the composition.

Abstract: Enhancement of pregnancy success in an animal is achieved by a method of treatment which includes administration of a single dose of melatonin during follicular development. An additional dose of melatonin can be administered during pregnancy to modulate accessory follicle formation. Novel compositions, which include a mixture of melatonin isomers or analogs, are also useful for enhancing pregnancy success.

Abstract: A method for treating pruritus comprising topical administration of formulation of vitamin D or an analog of vitamin D is disclosed. The formulation comprises a therapeutically effective, water-based emulsion, water-based suspension or oil-based formulation of vitamin D or analog of vitamin D.